Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

DUBLIN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling positive clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its next-generation continuous glucose monitoring (CGM) technology, called CGM+. For the first time, trial data confirms that Trinity Biotech’s redesigned proprietary needle-free glucose sensor delivers accurate glucose readings across a full 15-day wear period without the need for finger-stick calibration, while also facilitating an innovative CGM design that reduces disposable components, significantly lowering the cost of care compared to current leading market products. As the high cost of existing CGM devices continues to hinder widespread adoption, Trinity Biotech’s innovative approach is designed to enhance accessibility and increase utilization of CGM technology.

Read more at globenewswire.com